A Phase 1 interventional study of ALT-803 in Healthy, sponsored by Altor BioScience. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Altor BioScience (part of ImmunityBio, Inc.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single center, open-label, pharmacokinetic study of ALT-803 administered as a subQ injection to healthy volunteers.
Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.
First submitted before Altor BioScience became part of ImmunityBio, Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Signed Written
Study Population
Age and Reproductive Status
Exclusion Criteria:
Medical History and Concurrent Diseases
Prohibited Treatments and/or Restricted Therapies
Allergies and Adverse Drug Reaction
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1.0 mg/ml ALT-803
Drug: ALT-803
2.0 mg/ml ALT-803
Drug: ALT-803
Subjects randomized to Group A will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
PK Profile - Half-life (t½)
The period of time required for the concentration or amount of drug in the body to be reduced by one-half.
Time frame: Up to 192 hours
PK Profile - Apparent (Extravascular) Volume of Distribution (Vz/F)
Apparent volume of distribution is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration.
Time frame: Up to 192 hours
PK Profile - Apparent (Extravascular) Clearance (CL/F)
apparent (extravascular) clearance (CL/F)
Time frame: Up to 192 hours
PK Profile - Maximum Observed Concentration (Cmax)
maximum observed concentration (Cmax)
Time frame: Up to 192 hours
PK Profile - Time of the Observed Maximum Concentration (Tmax)
time of the observed maximum concentration (Tmax)
Time frame: Up to 192 hours
PK Profile - Area Under the Plasma Concentration Curve From Time 0 Through the Last Measurable Concentration (AUC0-t)
area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t)
Time frame: Up to 192 hours
PK Profile - Area Under the Plasma Concentration Curve From Time 0 Extrapolated to Infinite Time (AUC0-inf)
area under the plasma concentration curve from time 0 extrapolated to infinite time (AUC0-inf)
Time frame: Up to 192 hours
Number of Adverse Events
Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
Time frame: Up to 66 days
| Milestone | Group A | Group B |
|---|---|---|
| Started | 10 | 10 |
| Completed | 7 | 7 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
The period of time required for the concentration or amount of drug in the body to be reduced by one-half.
| Days | Group A | Group B |
|---|---|---|
| Period 1 (10 μg/kg) | 1.07 ± 0.813 | 0.55 ± 0.095 |
| Period 2 (20 μg/kg) | 1.02 ± 0.758 | 0.68 ± 0.236 |
Apparent volume of distribution is a ratio of the total amount of drug in the body to the plasma concentration of the drugs such that Vd = amount of drug in body/plasma drug concentration.
| mL/kg | Group A | Group B |
|---|---|---|
| Period 1 - 10 μg/kg | 13900 ± 12000 | 5360 ± 2790 |
| Period 2 - 20 μg/kg | 15500 ± 13000 | 11800 ± 8170 |
apparent (extravascular) clearance (CL/F)
| mL/day/kg | Group A | Group B |
|---|---|---|
| Period 1 - 10 µg/kg | 8650 ± 5450 | 6610 ± 2680 |
| Period 2 - 20 µg/kg | 10500 ± 5430 | 11000 ± 4440 |
maximum observed concentration (Cmax)
| pg/mL | Group A | Group B |
|---|---|---|
| Period 1 - 10 µg/kg | 1150 ± 945 | 1080 ± 902 |
| Period 2 - 20 µg/kg | 1900 ± 1930 | 1490 ± 921 |
time of the observed maximum concentration (Tmax)
| Days | Group A | Group B |
|---|---|---|
| Period 1 - 10 µg/kg | 0.167 (0.167 to 2.00) | 0.583 (0.167 to 2.00) |
| Period 2 - 20 µg/kg | 1.00 (0.170 to 1.00) | 0.170 (0.170 to 0.171) |
area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t)
| Day*pg/mL | Group A | Group B |
|---|---|---|
| Period 1 - 10 µg/kg | 1390 ± 727 | 1240 ± 706 |
| Period 2 - 20 µg/kg | 2370 ± 1410 | 1940 ± 1040 |
area under the plasma concentration curve from time 0 extrapolated to infinite time (AUC0-inf)
| Day*pg/mL | Group A | Group B |
|---|---|---|
| Period 1 - 10 µg/kg | 1600 ± 897 | 1740 ± 731 |
| Period 2 - 20 µg/kg | 2420 ± 1400 | 2130 ± 1000 |
Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
| Participants | Group A | Group B |
|---|---|---|
| Number of Adverse Events | 10 | 10 |
Collected over Up to 66 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Group B | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Event | Group A | Group B |
|---|---|---|
| ChillsGeneral disorders | 9/10 | 10/10 |
| Injection site reactionGeneral disorders | 10/10 | 10/10 |
| Feeling of body temperature changeGeneral disorders | 4/10 | 8/10 |
| PyrexiaGeneral disorders | 8/10 | 7/10 |
| Abdominal pain lowerGastrointestinal disorders | 7/10 | 7/10 |
| HeadacheNervous system disorders | 6/10 | 7/10 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/10 | 5/10 |
| Back painMusculoskeletal and connective tissue disorders | 1/10 | 4/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/10 | 1/10 |
| LymphadenopathyBlood and lymphatic system disorders | 3/10 | 3/10 |
| Age, Continuous(years) | Group A | Group B | Total |
|---|---|---|---|
| Median | 46 ± 11.3 | 42.5 ± 11.6 | 44 ± 11.4 |
| Sex: Female, Male(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 5 | 6 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 10 | 19 |
| Not Hispanic or Latino | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group A | Group B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 9 | 10 | 19 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Healthy Volunteers(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Count of participants | 10 | 10 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Mar 2018, 2 months.
Results were first posted in Mar 2025, 7 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nogapendekin alfa inbakicept